Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
Key Details
- 1Radiology Partners and Mosaic Clinical Technologies have submitted a citizen petition to the FDA.
- 2They seek clarity on FDA regulatory status for commercially available vision-language models in diagnostic imaging.
- 3Concerns are raised about the lack of standards for validating performance, safety, and transparency of such AI models.
- 4Current regulatory ambiguity places responsibility and risk on radiologists and downstream users.
- 5The petition asks the FDA to specify whether fine-tuned models require premarket clearance and clarify compliance duties for all stakeholders.
Why It Matters
Clear regulatory guidelines are crucial for ensuring the safety, effectiveness, and responsible deployment of AI models in diagnostic radiology. Standardized oversight will protect patients while supporting innovation and providing consistency for developers and healthcare organizations.
Source
Radiology Business
Related News
•AuntMinnie
Vast Majority of FDA-Cleared Radiology AI Devices Lack Outcome Trials
Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
•Radiology Business
FDA Solicits Public Input on Regulating Generative AI in Medical Devices
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.
•HealthExec
AI's Role in Eliminating Cervical Cancer: A Model for Disease Prevention
Researchers highlight how AI can accelerate the elimination of cervical cancer and set a precedent for combating other diseases.